CONNECT

ONCOLOGY REQUISITION

PATIENT INFORMATION				
				/ /
Patient Last Name	Patient First Name		MI	Date of Birth (MM / DD / YYYY)
Address		City	State	ZIP Code
			Patient discha	
Phone	Accession #	Hospital / Medical Record #	the hospital/f	
Genetic Sex: () Female () Male	e () Unknown Gender identity (if diffe	erent from left):	Ethnicity	(optional):
ACCOUNT INFORMATION				
Ordering Physician		Institution Name		
Email (Required for International Cli		Fax	Client ID	NPI #
ADDITIONAL REPORTING RECIP	PIENTS ·····			
Name		Email	Fax	
Name		Email	Fax	
BILLING INFORMATION (FILL OU				
Institution Name	Institution Code Inst	itution Contact Name	Institution Phone	Institution Contact Email
○ INSURANCE				
🗌 Do Not Perform Test Until	Patient is Aware of Out-Of-Pocket Costs			
REQUIRED ITEMS 1. Copy o	f the Front/Back of Insurance Card(s) 2. ICD10 / /	D Diagnosis Code(s) 3. Name of	Ordering Physician 4. Ir	nsured Signature of Authorization
Name of Insured	Insured Date of Birth (MM / DD / YYYY)	Name of Insured	Ir	usured Date of Birth (MM / DD / YYYY
Phone of Insured		Phone of Insured		
Address of Insured		Address of Insured		
City	State ZIP	City	S	tate ZIP
Primary Insurance Co. Name		Secondary Insurance (Co. Name	
Primary Member Policy #	Primary Member Group #	Secondary Member Po	olicy # S	econdary Member Group #
PHYISICIAN SIGNATURE AND CO	NSENT (REQUIRED)			
My signature below certifies that (1) the p	atient has received an explanation of the purpose, risks, urrent, relapsed, refractory, metastatic, or advanced stag			

Physician's Printed Name

Physician's Signature

in 🗙 🛈 🗲 🕩

ONCOLOGY REQUISITION

			//	
Patient Last Name	Patient First Name	MI	Date of Birth (MM / DD / YYYY)	Genetic Sex
SAMPLE INFORMATION				
Date of Collection (MM / DD / YYYY)	Time of Collection		only be accepted if the isolation of nucl laboratory or a laboratory meeting equ he CMS.	
SAMPLE TYPE ·····				
	Tissue in Medium [±] * () Tissue in Medium [±] * ttach a copy) () Yes () No OFILE PLUS, LIQUID TRACE HEMATOLO (es () No and indicate the percentage of tumor or blas 30 - 50% () >50% and concurrent laboratory reports (such as CB s available. all tissue samples but may be sent later as soon.	st nuclei in the sample: C, flow cytometry, cytogenetics, Fl		reports). Concurrent
INDICATION FOR TESTING (REQUIRED)				
INDICATION FOR TESTING (REQUIRED)				
Indication(s) Indication(s) Relapse/Refi BONE MARROW TRANSPLANT Biological Sex of Bone Marrow Transplant Dono	Autologous Allogeneic Se	ICD10 Diagnosis Code(s)] MRD ex Mismatch		
SPECIMEN RETRIEVAL				
	men (complete information below). To initiat e			
Institution		Contact Name		
Address		City	State ZI	P
Phone	Fax			

ONCOLOGY REQUISITION

Patient Last N	lame	Pat	ient First Name		MI	Date of Birth (MM / DD / YYYY)	Genetic Se
	dium Heparin (green-top)	BMH = Bone Marrow in S	odium Heparin (green-top)		DTA (purple-top)	BME = Bone Marrow in E	DTA (purple-top)
M = Tissue in M		FFPE = Slides/Block		T = Fresh Froze	en Tissue		
OMPREHEN	ISIVE PROFILES						
EST CODE	TEST NAME						SAMPLE TYP
25000	Hematology Profile Panel (D	NA)					BE, BME, FFF
25001	Hematology Profile Plus Pan	el (DNA + RNA)					BE, BME, FFF
25002	Liquid Trace Hematology Par	nel (cfDNA + cfRNA)					BE
YTOGENET	C TESTS						
	CHROMOSOME ANALYSIS •						
EST CODE							
8300	TEST NAME Hematologic Cancer						SAMPLE TYP BH, BMH
8050	Solid Tumor						ТМ
] 0050							1141
ISH PANEL	s						
EST CODE	TEST NAME						SAMPLE TYP
8789	Aggressive/High-Grade B-Ce	All Lymphoma (MYC t	ranslocation BCI 2 rear	rangement BCI	6 rearrangement)		FFPE
3 8010	ALL Adult (CDKN2A del, BCR)			-	-		BH, BMH
	☐ If the result is negative, re				, , , ,	,	
8012	ALL Ph-Like FISH Panel (PDG	FRb, BCR/ABL1-ASS	51, JAK2, EPOR, CRLF2)				BH, BMH
8792	ALL Pediatric (BCR/ABL transle	ocation, KMT2A rearra	angement, ETV6/RUNX1 t	ranslocation, Tris	omy 4, Trisomy 10,	TCF3/PBX1 amplification/deletion)	BM, BMH
8000	AML (Trisomy 8, AML/ETO, MI	LL rearrangement, P	ML/RARA, CBFB inversi	on)			BH, BMH
8001	STAT AML (RUNX1T1/RUNX1 tr	anslocation, KMT2A r	earrangement, PML/RAR	A translocation, C	BFB rearrangeme	nt, MECOM (EVI1) rearrangement)	BH, BMH
8040	CLL (Trisomy 12, ATM del, p53	3 del, MYB del, 13q de	el, IGH rearrangement, IO	GH/CCND1 fusion	1		BH, BMH
8791	Eosinophilia (PDGFRB rearrang	jement, FGFR1 rearra	ngement, JAK2 rearrange	ement, PDGFRA/C	HIC2/FIP1L1 rearra	ngement, CBFB rearrangement)	BH, BMH
8005	MDS (5 del, 7 del, Trisomy 8,	MLL rearrangement	, 20q del)				BH, BMH
8006	STAT MDS (5 del, 7 del, 20q de	l, p53 del, KMT2A rea	arrangement)				BH, BMH
8007	Comprehensive MDS/AML (5 o	del, 7 del, 20q del, p5	3 del, RUNX1T1/RUNX1, I	KMT2A, PML/RAF	A, CBFB, MECOM	EVI1)	BH, BMH
8008			•	(1T1 translocation	n, KMT2A rearrang	ement, PML/RARA translocation,	BH, BMH
8015	CBFB rearrangement, MECOM Multiple Myeloma (Trisomy 9			53 del, Trisomy 7	, CKS1B/CDKN2C	amplification/deletion)	BH, BMH
7 0700	If IGH rearrangement posi				• •		
8790	Multiple Myeloma IgH Rearra	-				.)	BH, BMH
8020	NHL (BCL6 rearrangement, I				nt, BCL2 rearrang	ement)	BH, BMH
8793	NTRK (NTRK1 rearrangemen	t, NTRK2 rearrange	ment, NTRK3 rearrange	ment)			FFPE
SINGLE FISI	H PROBES						
TEST CODE	TEST NAME		SAMPLE TYPE	TEST CODE	TEST NAME		SAMPLE TYP
8725	AML1/ETO: t(8;21) [AML]		BH, BMH	8765	IGH/BCL2 [t(14;	18)] FISH Analysis	BH, BMH, FFF
8785	BCL2 Rearrangement		BH, BMH, FFPE	8770	IGH/CCND1: t(11	;14) [Mantle Cell Lymphoma]	BH, BMH, FF
8775	BCL6 Rearrangement		BH, BMH, FFPE	8795	IGH/MYC Analys	is	BMH, FFPE
8750	BCR/ABL: t(9;22) [CML/ALL/A	ML]	BH, BMH	8786	MALT1 Lymphor		BH, BMH
8740	CBFB: inv(16) [AML]		BH, BMH	8705	MECOM (EVI1) A	nalysis	BH, BMH
8730	CHIC2: Deleted 4q [Hypereosing	ophilic Syndrome]	BH, BMH	8745	MLL: 11q23		BH, BMH
8710	Deletion 5: [MDS]	-	BH, BMH	8760	MYC translocatio	ก	BH, BMH, FFF
8715	Deletion 7: [MDS]		BH, BMH	8788	p53		BH, BMH
8720	Deletion 20q12: [MDS]		BH, BMH	8735	PML/RARA: t(15	;17) [AML]	BH, BMH
8065	DXZ1/DYZ3		BH, BMH	8781	ROS1 Rearrange		FFPE
8385	Gain Chromosome 8		BH, BMH	8755	TEL/AML1: t(12;		BH, BMH
	0 00000110 0		2.1, 2.11		· / / / / / / / / / / / / / / / / /		51, 501

connect in $X \bigcirc \bigcirc \square$

ONCOLOGY REQUISITION

SAMPLE SPECIFICATIONS TABLE

FOR CLIENT INFORMATION ONLY. Not required with sample submission.

ABBREVIATION	SAMPLENAME	RECOMMEN	DED AMOUNT	- SHIPPING INSTRUCTIONS	SPECIAL NOTES
Abbite HArrow		(2 YRS - ADULT)	(NEWBORN - 2YRS)		
BE	Blood in EDTA tube (purple-top)	3 - 5 cc	2 -3 cc	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 24-48 hours of collection.	Attach clinical notes and concurrent laboratory reports (such as CBC, flow cytometry, cytogenetics, FISH, molecular testing, and pathology reports). Concurrent laboratory results may be sent later as soon as available.
ВН	Blood in Sodium Heparin tube (green-top)	3 - 5 cc	2 -3 cc	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 24-48 hours of collection.	Attach clinical notes and concurrent laboratory reports (such as CBC, flow cytometry, cytogenetics, FISH, molecular testing, and pathology reports). Concurrent laboratory results may be sent later as soon as available.
BME	Bone Marrow in EDTA tube (purple-top)	3 - 5 cc	2 -3 cc	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 24-48 hours of collection.	Attach clinical notes and concurrent laboratory reports (such as CBC, flow cytometry, cytogenetics, FISH, molecular testing, and pathology reports). Concurrent laboratory results may be sent later as soon as available.
ВМН	Bone Marrow in Sodium Heparin tube (green-top)	3 - 5 cc	2 -3 cc	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 24-48 hours of collection.	Attach clinical notes and concurrent laboratory reports (such as CBC, flow cytometry, cytogenetics, FISH, molecular testing, and pathology reports). Concurrent laboratory results may be sent later as soon as available.
DNA	DNA, Extracted	At Least 100 ng	At Least 100 ng	Ship at room or refrigerated temperature in an insulated container by overnight courier. May also be shipped frozen on minimum of 10 lbs of dry ice in an insulated container by overnight courier.	Minimum concentration of 25ng/uL. Attach clinical notes, concurrent laboratory reports, and/or surgical pathology report, as applicable. Please send a corresponding representative H+E slide, if available.
FFPE	FFPE - Block	See Special Notes	See Special Notes	Ship at room temperature in an insulated container by overnight courier. If shipping during the summer months please include a cold-pack to avoid extreme temperatures. Do not heat or freeze.	Paraffin-embedded, formalin-fixed tissue block containing ≥20% tumor nuclei with a minimum tumor surface area of 5mm x 5mm (25mm ²). Decalcified specimens are not accepted. Surgical pathology report must be attached for all tissue samples.
FFPE	FFPE - Slides	See Special Notes	See Special Notes	Ship at room temperature in an insulated container by overnight courier. If shipping during the summer months please include a cold-pack to avoid extreme temperatures. Do not heat or freeze.	10 - 15 unstained 5µm FFPE slides containing ≥20% tumor nuclei with a minimum tumor surface area of 5mm x 5mm (25mm²). For smaller specimens, 20 or more unstained 5µm FFPE slides containing ≥20% tumor nuclei should be submitted. Decalcified specimens are not accepted. Surgical pathology report must be attached for all tissue samples.
					For test codes 9505: 20 slides are required for submission.
RNA	RNA, Extracted	At Least 100 ng	At Least 100 ng	Ship frozen on minimum of 10 lbs of dry ice in an insulated container by overnight courier.	Minimum concentration of 25ng/uL. Attach clinical notes, concurrent laboratory reports, and/or surgical pathology report, as applicable. Please send a corresponding representative H+E slide, if available.
SA	Saliva	See Special Notes	See Special Notes	Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.	Collected with Oragene DNA Self-Collection Kit (provided by Baylor Genetics with instructions).
Т	Fresh Frozen Tissue	150 mg	150 mg	Ship frozen on minimum of 10 lbs of dry ice in an insulated container by overnight courier.	Fresh tissue snap frozen at ≤-20°C. Store at ≤-20°C. Surgical pathology report must be attached for all tissue samples. Surgical pathology report may be sent later as soon as it becomes available. Please send a corresponding representative H+E slide, if available.
ТМ	Fresh Tissue in Medium	0.5 - 1 cm³ or more	0.5 - 1 cm³ or more	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 48 hours of collection.	Transport tumor tissue in a sterile, screw-top container filled with tissue culture transport medium. If tissue culture transport medium is not available, collect in plain RPMI, Hanks solution, or saline. Surgical pathology report must be attached for all tissue samples. Surgical pathology report may be sent later as soon as it becomes available. Please send a corresponding representative H+E slide, if available.

INFORMED CONSENT FOR ONCOLOGY TESTING

				/ /		
Patient Last Name		Patient First Name	MI	Date of Birth (MM / DD / YYYY)	Genetic Sex	
TEST INFORMATION	•••••••••••••••••••••••••••••••••••••••					

This consent form will provide you with information regarding genetic testing, which you should discuss with your healthcare provider or a genetic counselor. To assist you in understanding the reason for this testing, we have provided information about the testing process and potential results below.

The purpose of genetic testing is to determine if a genetic disease may be present or if there is an increased risk for a genetic disease to occur in a patient or their family. DNA is the genetic material that we receive from our parents. Genes are made of DNA and are the instructions for maintaining the health of our body. Each person has a unique set of DNA and most of the differences in our DNA do not impact our health. Genetic testing analyzes DNA to find any abnormal changes (mutations also called variants) that might cause disease, make it more likely to develop disease, and/or increase the chance of having a child affected by disease.

The testing ordered by your healthcare provider can determine if you or your child have a variant associated with a genetic disease. "Your child" can also mean your unborn child, for the purposes of this consent.

Depending on why genetic testing is needed, you might be tested for:

- A known variant that has already been found in your family
- A single gene or variant that causes a specific, suspected disease.
- Multiple genes at the same time. These genes might cause similar diseases or might cause diseases that are unrelated to each other.
- Multiple types of testing that each test for different variants.

RESULTS ·····

There are several types of test results that may be reported including:

- Positive: Positive or "abnormal" results mean there is a change in the DNA found that is related to your/your child's medical issues or that you/your child are at an increased risk of developing a disease in the future. It is possible to test positive for more than one variant. Positive results might include pathogenic variants (variants known to be associated with disease) and likely pathogenic variants (variants that are likely to be associated with disease).
- Negative: Negative or "normal" results mean no relevant variants related to your/your child's medical issues were detected or that you/your child are not expected to be at an increased risk for developing a disease in the future. This might indicate that there are no variants associated with disease in the gene(s) tested. Genetic testing, while highly accurate, might not detect a variant present in the gene(s) tested. This can be due to limitations of the information available about the gene(s) being tested, or limitations of the testing technology.
- Variant of Uncertain Significance: Testing can detect variant(s) in DNA which we do not yet fully understand. These are also referred to as variants of
 uncertain significance (VUS). Additional testing may be recommended for you or your family if a VUS is identified in a gene that may be associated with
 your/your child's medical condition.
- Secondary / Incidental Findings: Testing can sometimes detect a variant in a person's DNA unrelated to the reason for testing. If this variant is expected to have medical or reproductive significance, it is called a secondary or incidental finding.

CONSIDERATIONS AND LIMITATIONS ······

- This consent form cannot be used for whole exome sequencing (WES), whole genome sequencing (WGS), or Huntington's disease testing. These tests have specific consents that are located at https://www.baylorgenetics.com/consent/.
- Results may indicate you have a genetic disease, are at increased risk to develop a genetic disease, and/or be at an increased risk to have a child with a
 genetic disease. It is important to understand that genetic tests, even if negative, cannot rule out every variant. It is not possible to exclude risks for all
 genetic diseases for you and your family members.
- Depending on the type of genetic testing performed and the results, additional genetic testing or other testing may be needed to fully understand the
 likelihood of your developing the disease or the severity of the disease. This additional testing might be needed for you/your child or other members of
 your family.
- It is recommended that you discuss genetic testing with your healthcare provider or genetic counselor before signing this consent and again after results are made available.
- It may not always be possible to complete testing. as sometimes the sample does not have enough DNA to perform testing or other reasons. In these cases, another sample may need to be sent to the laboratory to perform testing.

PATIENT CONFIDENTIALITY AND SPECIMEN RETENTION

• If several family members are tested, the correct interpretation of the results depends on the information provided about the relationships amongst family members. In rare cases, genetic testing can reveal that the true biological relationships in a family are not as they were reported. If a difference is identified, it may be necessary to share this information with the healthcare provider who ordered the testing.

INFORMED CONSENT FOR ONCOLOGY TESTING

			//	
Patient Last Name	Patient First Name	МІ	Date of Birth (MM / DD / YYYY)	Genetic Sex
PATIENT CONFIDENTIALITY AND SPECIMEN RETENT	FION (CONT.) ••••••			

- Genetic testing is highly accurate, however in rare cases, inaccurate results may occur. Reasons for this include, but are not limited to, mislabeled samples, inaccurate reporting of clinical/medical information, or rare technical errors.
- If you sign this consent form, but you no longer wish to have your sample(s) tested, you can contact the healthcare provider who ordered the test to
 cancel the test. If you wish to cancel testing, the laboratory must be notified of the cancellation request before 5 PM CST the business day after the
 sample has begun testing. If the laboratory is not notified of your cancellation request until after this time, you will be charged for the full cost of the
 test.
- Only Baylor Genetics and Baylor Genetics contracted partners will have access to the sample(s) provided to conduct the requested testing. Results
 will only be released to the following person(s): (i) a licensed healthcare provider, (ii) those authorized in writing, (iii) the patient or their personal
 representative, and (iv) those allowed access to test results by law. I understand that I have the right to access any test results directly from Baylor
 Genetics by providing a written request. I also understand that laboratory raw data, while not routinely released as part of the testing process, can be
 requested by providing a written request or HIPAA Authorization Form.
- In rare cases, persons with genetic diagnoses have experienced problems with insurance coverage and employment. The U.S. Federal Government has enacted several laws that prohibit discrimination based on genetic test results by health insurance companies and employers. In addition, these laws prohibit unauthorized disclosure of this information. For more information, you can visit www.genome.gov/10002077.
- Samples will be retained in the laboratory in accordance with the laboratory retention policy.
- After testing is complete, the de-identified submitted specimen may be used for test development and improvement, internal validation, quality assurance, and training purposes. DNA specimens are not returned to individuals or to referring heath care providers unless specific prior arrangements have been made.
- Samples from residents of New York State will not be included in research studies without your written consent and will not be retained for more than 60 days after receipt of the sample. No tests other than those authorized shall be performed on the biological sample.
- By signing this consent form, I understand and agree that variants identified may also be submitted to public databases, such as ClinVar. Such
 submission serves to contribute knowledge to the medical community. I understand that limited clinical information is also required for the submission
 of information to ClinVar's database and further that the contents of this limited clinical information may, although unlikely, include information that may
 identify me personally.
- It is possible that even if the test identifies the underlying genetic cause for the disease in your family, this information may not help in predicting the progression of disease or change management or treatment of disease.

FINANCIAL AGREEMENT AND GUARANTEE

By signing this consent form, I accept full and complete financial responsibility for all genetic testing ordered by my healthcare provider. For insurance billing, I hereby authorize Baylor Genetics to bill my health insurance plan on my behalf, and further authorize Baylor Genetics to release any information to my insurance carrier which is reasonably required for billing. I additionally designate Baylor Genetics as my designated representative for purposes of appealing any denial of benefits by my insurance carrier. I irrevocably assign associated payment to Baylor Genetics, and direct that payment be made directly to Baylor Genetics. I understand that my out-of-pocket costs may be different than the estimated amount indicated to me by Baylor Genetics as part of a verification of benefits investigation. I agree to be financially responsible for all amounts as indicated on the explanation of benefits issued by my health insurance plan. If my insurance provider sends a payment directly to Baylor Genetics within thirty (30) days of receipt thereof, as payment towards Baylor Genetics' claim for services rendered. If I do not have health insurance, I agree to pay for the full cost of the genetic testing that was ordered by my healthcare provider and billed to me by Baylor Genetics.

I understand that a completed Advance Beneficiary Notice (ABN) is required for Medicare patients if the service is deemed not medically necessary.

RECONTACT FOR RESEARCH CONSENT

Baylor Genetics participates in research relating to health, disease prevention, drug development, and other scientific purposes. Baylor Genetics may contact patients or their provider(s) directly as part of this research. I agree to allow Baylor Genetics to contact me or my provider(s) about possible research involving the sample(s) and/or information associated with this testing. I understand that patients generally receive no compensation for this participation in research. For more information on research at Baylor Genetics, please visit baylorgenetics.com.

If I wish to opt out of being recontacted for research purposes by Baylor Genetics, I understand that I may check the box below:

□ Please do not contact me regarding any research that uses information obtained from this testing.

For any research I may be contacted about, I prefer contact through the following methods (please check all that apply – if no choices are selected, contact will be made via secure email if possible):

□Email □Phone □Mail

INFORMED CONSENT FOR ONCOLOGY TESTING

			/ /	
Patient Last Name	Patient First Name	MI	Date of Birth (MM / DD / YYYY)	Genetic Sex
PATIENT AUTHORIZATION				

By signing this statement of consent, I acknowledge that I have read, understand, and hereby grant my informed consent for genetic testing. I have received appropriate explanations from my healthcare provider about the planned genetic test(s) and possible results. I have been informed by my healthcare provider about the availability and importance of genetic counseling and have been provided with written information identifying a genetic counselor or medical geneticist who can provide such counseling services. All my questions have been answered and I have had the necessary time to make an informed decision about the genetic test(s).

I hereby give permission to Baylor Genetics to conduct genetic testing as recommended by my physician.

		/		/
Patient's Printed Name	Patient's Signature	Date (MM /	DD / Y	YYY)
		/		/
Patient's Parent / Personal Representative* Name	Patient's Parent / Personal Representative Signature	Date (MM /	DD / Y	YYY)
		/		/
Relationship of Personal Representative to the Patient	Ordering Provider's Signature	Date (MM /	DD / Y	YYY)

*If you are signing as a person with legal authority to act on behalf of the patient, you may be required to provide evidence of your authority.